Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Am J Hum Genet ; 96(1): 136-46, 2015 Jan 08.
Artigo em Inglês | MEDLINE | ID: mdl-25574827

RESUMO

Type 1 narcolepsy, a disorder caused by a lack of hypocretin (orexin), is so strongly associated with human leukocyte antigen (HLA) class II HLA-DQA1(∗)01:02-DQB1(∗)06:02 (DQ0602) that very few non-DQ0602 cases have been reported. A known triggering factor for narcolepsy is pandemic 2009 influenza H1N1, suggesting autoimmunity triggered by upper-airway infections. Additional effects of other HLA-DQ alleles have been reported consistently across multiple ethnic groups. Using over 3,000 case and 10,000 control individuals of European and Chinese background, we examined the effects of other HLA loci. After careful matching of HLA-DR and HLA-DQ in case and control individuals, we found strong protective effects of HLA-DPA1(∗)01:03-DPB1(∗)04:02 (DP0402; odds ratio [OR] = 0.51 [0.38-0.67], p = 1.01 × 10(-6)) and HLA-DPA1(∗)01:03-DPB1(∗)04:01 (DP0401; OR = 0.61 [0.47-0.80], p = 2.07 × 10(-4)) and predisposing effects of HLA-DPB1(∗)05:01 in Asians (OR = 1.76 [1.34-2.31], p = 4.71 × 10(-05)). Similar effects were found by conditional analysis controlling for HLA-DR and HLA-DQ with DP0402 (OR = 0.45 [0.38-0.55] p = 8.99 × 10(-17)) and DP0501 (OR = 1.38 [1.18-1.61], p = 7.11 × 10(-5)). HLA-class-II-independent associations with HLA-A(∗)11:01 (OR = 1.32 [1.13-1.54], p = 4.92 × 10(-4)), HLA-B(∗)35:03 (OR = 1.96 [1.41-2.70], p = 5.14 × 10(-5)), and HLA-B(∗)51:01 (OR = 1.49 [1.25-1.78], p = 1.09 × 10(-5)) were also seen across ethnic groups in the HLA class I region. These effects might reflect modulation of autoimmunity or indirect effects of HLA class I and HLA-DP alleles on response to viral infections such as that of influenza.


Assuntos
Cadeias beta de HLA-DP/genética , Antígenos de Histocompatibilidade Classe I/genética , Narcolepsia/genética , Alelos , Povo Asiático , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Loci Gênicos , Antígenos HLA-B/genética , Antígenos HLA-B/metabolismo , Antígenos HLA-DP/genética , Antígenos HLA-DP/metabolismo , Cadeias beta de HLA-DP/metabolismo , Cadeias alfa de HLA-DQ/genética , Cadeias alfa de HLA-DQ/metabolismo , Antígenos HLA-DR/genética , Antígenos HLA-DR/metabolismo , Haplótipos , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Vírus da Influenza A Subtipo H1N1/genética , Masculino , Fatores de Risco , População Branca
2.
PLoS Genet ; 9(2): e1003270, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23459209

RESUMO

Recent advances in the identification of susceptibility genes and environmental exposures provide broad support for a post-infectious autoimmune basis for narcolepsy/hypocretin (orexin) deficiency. We genotyped loci associated with other autoimmune and inflammatory diseases in 1,886 individuals with hypocretin-deficient narcolepsy and 10,421 controls, all of European ancestry, using a custom genotyping array (ImmunoChip). Three loci located outside the Human Leukocyte Antigen (HLA) region on chromosome 6 were significantly associated with disease risk. In addition to a strong signal in the T cell receptor alpha (TRA@), variants in two additional narcolepsy loci, Cathepsin H (CTSH) and Tumor necrosis factor (ligand) superfamily member 4 (TNFSF4, also called OX40L), attained genome-wide significance. These findings underline the importance of antigen presentation by HLA Class II to T cells in the pathophysiology of this autoimmune disease.


Assuntos
Apresentação de Antígeno , Doenças Autoimunes , Narcolepsia/genética , Receptores de Antígenos de Linfócitos T alfa-beta , Apresentação de Antígeno/genética , Apresentação de Antígeno/imunologia , Doenças Autoimunes/genética , Doenças Autoimunes/imunologia , Doenças Autoimunes/metabolismo , Estudos de Associação Genética , Antígenos HLA/genética , Antígenos HLA/imunologia , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/genética , Peptídeos e Proteínas de Sinalização Intracelular/imunologia , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Narcolepsia/imunologia , Narcolepsia/fisiopatologia , Neuropeptídeos/genética , Neuropeptídeos/imunologia , Neuropeptídeos/metabolismo , Orexinas , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Receptores de Antígenos de Linfócitos T alfa-beta/metabolismo , População Branca
3.
Nat Commun ; 14(1): 2709, 2023 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-37188663

RESUMO

Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix®. Here, we dissect disease mechanisms and interactions with environmental triggers in a multi-ethnic sample of 6,073 cases and 84,856 controls. We fine-mapped GWAS signals within HLA (DQ0602, DQB1*03:01 and DPB1*04:02) and discovered seven novel associations (CD207, NAB1, IKZF4-ERBB3, CTSC, DENND1B, SIRPG, PRF1). Significant signals at TRA and DQB1*06:02 loci were found in 245 vaccination-related cases, who also shared polygenic risk. T cell receptor associations in NT1 modulated TRAJ*24, TRAJ*28 and TRBV*4-2 chain-usage. Partitioned heritability and immune cell enrichment analyses found genetic signals to be driven by dendritic and helper T cells. Lastly comorbidity analysis using data from FinnGen, suggests shared effects between NT1 and other autoimmune diseases. NT1 genetic variants shape autoimmunity and response to environmental triggers, including influenza A infection and immunization with Pandemrix®.


Assuntos
Doenças Autoimunes , Vírus da Influenza A Subtipo H1N1 , Vacinas contra Influenza , Influenza Humana , Narcolepsia , Humanos , Autoimunidade/genética , Influenza Humana/epidemiologia , Influenza Humana/genética , Vírus da Influenza A Subtipo H1N1/genética , Doenças Autoimunes/epidemiologia , Doenças Autoimunes/genética , Vacinas contra Influenza/efeitos adversos , Narcolepsia/induzido quimicamente , Narcolepsia/genética
4.
Sleep ; 33(11): 1457-64, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21102987

RESUMO

STUDY OBJECTIVE: to report on symptoms and therapies used in childhood narcolepsy-cataplexy. DESIGN, PATIENTS, AND SETTING: retrospective series of 51 children who completed the Stanford Sleep Inventory. HLA-DQB1*0602 typing (all tested, and 100% positive), polysomnography or Multiple Sleep Latency Test (76%), and cerebrospinal fluid hypocretin-1 measurements (26%, all with low levels) were also conducted. Prospective data on medication response was collected in 78% using a specially designed questionnaire. MEASUREMENTS AND RESULTS: patients were separated into children with onset of narcolepsy prior to (53%), around (29%), and after (18%) puberty. None of the children had secondary narcolepsy. Clinical features were similar across puberty groups, except for sleep paralysis, which increased in frequency with age. Common features included excessive weight gain (84% ≥ 4 kg within 6 months of onset of narcolepsy) and earlier puberty (when compared with family members), notably in subjects who gained the most weight. Streptococcus-positive throat infections were reported in 20% of cases within 6 months of onset of narcolepsy. Polysomnographic features were similar across groups, but 3 prepubertal children did not meet Multiple Sleep Latency Test diagnostic criteria. Regarding treatment, the most used and continued medications were modafinil (84% continued), sodium oxybate (79%), and venlafaxine (68%). Drugs such as methylphenidate, tricyclic antidepressants, or selective serotonin reuptake inhibitors were often tried but rarely continued. Modafinil was reported to be effective for treating sleepiness, venlafaxine for cataplexy, and sodium oxybate for all symptoms, across all puberty groups. At the conclusion of the study, half of children with prepubertal onset of narcolepsy were treated "off label" with sodium oxybate alone or with the addition of one other compound. In older children, however, most patients needed more than 2 drugs. CONCLUSION: this study reports on the clinical features of childhood narcolepsy and documents the safe use of treatments commonly used in adults in young children.


Assuntos
Narcolepsia/diagnóstico , Narcolepsia/tratamento farmacológico , Adjuvantes Anestésicos/uso terapêutico , Adolescente , Distribuição por Idade , Idade de Início , Antidepressivos de Segunda Geração/uso terapêutico , Compostos Benzidrílicos/uso terapêutico , Estimulantes do Sistema Nervoso Central/uso terapêutico , Criança , Cicloexanóis/uso terapêutico , Proteínas de Drosophila , Quimioterapia Combinada/métodos , Quimioterapia Combinada/estatística & dados numéricos , Feminino , Seguimentos , Humanos , Masculino , Modafinila , Narcolepsia/epidemiologia , Proteínas do Tecido Nervoso , Proteínas Nucleares , Sobrepeso/epidemiologia , Polissonografia/métodos , Polissonografia/estatística & dados numéricos , Puberdade , Estudos Retrospectivos , Oxibato de Sódio/uso terapêutico , Infecções Estreptocócicas/epidemiologia , Inquéritos e Questionários , Fatores de Transcrição , Estados Unidos/epidemiologia , Cloridrato de Venlafaxina , Aumento de Peso
5.
J Clin Sleep Med ; 14(1): 65-74, 2018 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-29198301

RESUMO

STUDY OBJECTIVES: To examine repeatability of Multiple Sleep Latency Test (MSLT) results in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) according to the criteria of the International Classification of Sleep Disorders, Third Edition (ICSD-3). METHODS: Repeatability of the MSLT was retrospectively evaluated in NT1 (n = 60) and NT2 (n = 54) cases, and controls (n = 15). All subjects had documented HLA-DQB1*06:02 status and/or hypocretin-1 levels from cerebrospinal fluid. All subjects had undergone 2 MSLTs (≥ 1 meeting ICSD-3 criteria for narcolepsy). Repeatability was explored in children versus adults and in those on versus not on medication(s). Subsample and multivariate analysis were performed. RESULTS: Both MSLTs in unmedicated patients were positive for narcolepsy in 78%, 18%, and 7% of NT1, NT2, and controls, respectively. NT2 cases changed to idiopathic hypersomnia or to a negative MSLT 26% and 57% of the time, respectively. Although NT1 cases were 10 to 14 times more likely to demonstrate a second positive MSLT compared to NT2 cases (P < 10-5) and controls (P < 10-4), respectively, NT2 cases were not significantly different from controls (P = .64). Medication use (P = .009) but not adult versus children status (P = .85) significantly decreased the likelihood of a repeat positive MSLT. CONCLUSIONS: In a clinical setting, a positive MSLT for narcolepsy is a more reproducible and stable feature in NT1 than NT2. The retrospective design of this study hinders interpretation of these data, as there are many different, and possibly opposing, reasons to repeat a MSLT in NT1 versus NT2 (ie, ascertainment bias). Additional systematic MSLT repeatability studies independent of confounds are ideally needed to confirm these findings.


Assuntos
Narcolepsia/diagnóstico , Polissonografia/métodos , Polissonografia/estatística & dados numéricos , Adulto , Fatores Etários , Criança , Feminino , Humanos , Masculino , Reprodutibilidade dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade
6.
Hum Immunol ; 68(1): 59-68, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17207713

RESUMO

The association of narcolepsy with HLA-DQB1*0602 is established in Japanese, African-Americans, European, and North American Caucasians. We examined DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1 in 163 patients with centrally mediated daytime sleepiness (100 with narcolepsy) and 211 Korean controls. In this population, the DQB1*0602 association was always evident in the context of the DRB1*1501-DQA1*0102-DQB1*0602 haplotype. The DQB1*0602 association was highest in cases with hypocretin deficiency (100% vs 13% in controls), most of which had narcolepsy-cataplexy (81%). A weaker DQB1*0602 (45%) association was present in cases without cataplexy. No human leukocyte antigen (HLA) association was present in idiopathic hypersomnia or in cases with normal cerebrospinal fluid (CSF) hypocretin-1. As in other populations, DQB1*0602 homozygosity increased risk in cases with cataplexy and/or hypocretin deficiency (odds ratio = 2.0 vs heterozygotes). Non-DQB1*0602 allelic effects were also observed but could not be interpreted in the context of DQB1*0602 overabundance and linkage disequilibrium. We therefore next analyzed compound heterozygote effects in 77 subjects with either hypocretin deficiency or cataplexy and one copy of DRB1*1501-DQA1*0102-DQB1*0602, a sample constructed to maximize etiologic homogeneity. In this analysis, we found additional predisposing effects of DQB1*0301 and protective effects for DQA1*0103-DQB1*0601. Unexpectedly, the predisposing effects of DQB1*0301 were present in the context of various DQA1-bearing haplotypes. A predisposing effect of DQA1*0303 was also suggested. These results indicate a remarkable consistency in the complex HLA association present in narcolepsy across multiple ethnic groups.


Assuntos
Predisposição Genética para Doença , Antígenos HLA-DQ/fisiologia , Glicoproteínas de Membrana/fisiologia , Narcolepsia/genética , Narcolepsia/metabolismo , Antígenos HLA-DQ/genética , Cadeias alfa de HLA-DQ , Cadeias beta de HLA-DQ , Humanos , Coreia (Geográfico) , Glicoproteínas de Membrana/genética
7.
Sleep ; 29(11): 1429-38, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17162989

RESUMO

STUDY OBJECTIVE: To study DQB1*0602 status and hypocretin-1 levels in the cerebrospinal fluid (CSF) in a cohort of patients with hypersomnolence and to test International Classification of Sleep Disorders-2 (ICSD-2) criteria for hypersomnia of central origin. DESIGN: Retrospective case series. PATIENTS AND SETTING: One hundred sixty-three consecutive patients with unexplained sleepiness and 282 controls recruited at St. Vincent's Hospital, Korea. The gold standard for diagnosis was ICSD-2 criteria. Patients and controls completed the Stanford Sleep Inventory, and agreed to HLA typing. Polysomnography (87%), Multiple Sleep Latency Test (MSLT) (96%), and CSF hypocretin-1 measurements (53%) were conducted in patients. MEASUREMENTS AND RESULTS: Most patients (80%) could be classified using the ICSD-2. The 33 patients who could not be classified were without cataplexy (4 with low CSF hypocretin-1). These could not be included because of sleep apnea (apnea-hypopnea index > or = 5/h, 84%) and/or because sleep prior to MSLT was less than 6 hours (27%). Narcolepsy with cataplexy cases were 92% HLA positive with low hypocretin-1. Cataplexy at interview was predicted by validated Stanford Sleep Inventory questions regarding cataplexy triggers. In contrast, cataplexy-like events were frequently reported in all groups, including controls. Cases with narcolepsy without cataplexy were frequently men (73%) and heterogeneous biologically (36% HLA positive, 40% with low CSF hypocretin-1). None of the controls had low CSF hypocretin-1, whereas 13% were HLA positive. CONCLUSION: The ICSD-2 was easily applicable in cases with typical cataplexy. In these cases, the MSLT and further evaluations were almost always positive and may thus not always be needed. Many patients without cataplexy were difficult to classify because of difficulties in interpreting the MSLT in the presence of sleep apnea or reduced sleep.


Assuntos
Distúrbios do Sono por Sonolência Excessiva/diagnóstico , Antígenos HLA-DQ/genética , Teste de Histocompatibilidade , Glicoproteínas de Membrana/genética , Narcolepsia/diagnóstico , Polissonografia , Receptores Acoplados a Proteínas G/deficiência , Receptores de Neuropeptídeos/deficiência , Adulto , Cataplexia/líquido cefalorraquidiano , Cataplexia/diagnóstico , Cataplexia/genética , Diagnóstico Diferencial , Distúrbios do Sono por Sonolência Excessiva/líquido cefalorraquidiano , Distúrbios do Sono por Sonolência Excessiva/genética , Feminino , Genótipo , Cadeias beta de HLA-DQ , Haplótipos , Humanos , Coreia (Geográfico) , Masculino , Narcolepsia/líquido cefalorraquidiano , Narcolepsia/genética , Receptores de Orexina , Valor Preditivo dos Testes
8.
Sleep ; 29(8): 1017-24, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16944669

RESUMO

STUDY OBJECTIVE: To determine if hypocretin deficiency is associated with abnormally low serum leptin levels, a putative cause of increased body mass index in narcoleptics. DESIGN: Cross-sectional controlled study. PARTICIPANTS: Three hundred seventy subjects, including 111 healthy controls, 93 narcoleptic subjects with hypocretin deficiency (cerebrospinal fluid [CSF] hypocretin-1 levels < 110 pg/mL), 72 narcoleptic subjects with normal hypocretin levels, and 89 subjects with other sleep disorders INTERVENTION: After completing the Stanford Sleepiness Inventory, participants underwent spinal taps and blood sampling for measurement of CSF leptin and hypocretin-1 levels, HLA DQB1*0602 phenotyping, and serum leptin and C-reactive protein levels. RESULTS: Serum leptin levels were similar in narcoleptic subjects, whether hypocretin-deficient (13.2 +/- 1.7 ng/mL, mean +/- SEM) or not (13.0 +/- 1.8 ng/mL), controls (10.1 +/- 1.1 ng/mL) and subjects with other sleep disorders (11.5 +/- 1.6 ng/mL). Similarly, the CSF leptin levels and the CSF: serum leptin ratios (an indicator of brain leptin uptake) were not different between groups. Serum and CSF leptin levels were higher in women and in subjects with higher body mass indexes. Leptin brain uptake decreased in women, in the aged, and in more-obese subjects. In contrast with a presumed inhibitory effect of leptin on hypocretin-containing cells, CSF leptin levels tended to correlate positively with CSF hypocretin-1 levels. C-reactive protein was higher (4.2 +/- 0.9 mg/L) in narcoleptic subjects with hypocretin deficiency than in controls (1.4 +/- 0.3 mg/L, p = .0055), a difference still significant after adjustment on confounding factors. DISCUSSION: Our data do not support a role for leptin in mediating increased body mass index in narcolepsy. A moderate but selective increase in C-reactive protein in hypocretin-1 deficient subjects should prompt research on inflammation in narcolepsy.


Assuntos
Barreira Hematoencefálica/fisiologia , Leptina/metabolismo , Narcolepsia/fisiopatologia , Receptores Acoplados a Proteínas G/deficiência , Receptores de Neuropeptídeos/deficiência , Adulto , Índice de Massa Corporal , Encéfalo/fisiopatologia , Proteína C-Reativa/metabolismo , Estudos Transversais , Feminino , Antígenos HLA-DQ/genética , Cadeias beta de HLA-DQ , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/fisiopatologia , Receptores de Orexina , Fenótipo , Receptores Acoplados a Proteínas G/metabolismo , Receptores para Leptina , Receptores de Neuropeptídeos/metabolismo , Valores de Referência , Fatores Sexuais , Transtornos do Sono-Vigília/fisiopatologia
10.
Sleep ; 38(11): 1673-81, 2015 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-26158891

RESUMO

STUDY OBJECTIVES: Although narcolepsy affects 0.02-0.05% of individuals in various ethnic groups, clinical presentation in different ethnicities has never been fully characterized. Our goal was to study phenotypic expression across ethnicities in the United States. DESIGN/SETTING: Cases of narcolepsy from 1992 to 2013 were identified from searches of the Stanford Center for Narcolepsy Research database. International Classification of Sleep Disorders, Third Edition diagnosis criteria for type 1 and type 2 narcolepsy were used for inclusion, but subjects were separated as with and without cataplexy for the purpose of data presentation. Information extracted included demographics, ethnicity and clinical data, HLA-DQB1*06:02, polysomnography (PSG), multiple sleep latency test (MSLT) data, and cerebrospinal fluid (CSF) hypocretin-1 level. PATIENTS: 182 African-Americans, 839 Caucasians, 35 Asians, and 41 Latinos with narcolepsy. RESULTS: Sex ratio, PSG, and MSLT findings did not differ across ethnicities. Epworth Sleepiness Scale (ESS) score was higher and age of onset of sleepiness earlier in African Americans compared with other ethnicities. HLA-DQB1*06:02 positivity was higher in African Americans (91.0%) versus others (76.6% in Caucasians, 80.0% in Asians, and 65.0% in Latinos). CSF hypocretin-1 level, obtained in 222 patients, was more frequently low (≤ 110 pg/ml) in African Americans (93.9%) versus Caucasians (61.5%), Asians (85.7%) and Latinos (75.0%). In subjects with low CSF hypocretin-1, African Americans (28.3%) were 4.5 fold more likely to be without cataplexy when compared with Caucasians (8.1%). CONCLUSIONS: Narcolepsy in African Americans is characterized by earlier symptom onset, higher Epworth Sleepiness Scale score, higher HLA-DQB1*06:02 positivity, and low cerebrospinal fluid hypocretin-1 level in the absence of cataplexy. In African Americans, more subjects without cataplexy have type 1 narcolepsy.


Assuntos
Negro ou Afro-Americano/estatística & dados numéricos , Narcolepsia/epidemiologia , Adulto , Negro ou Afro-Americano/genética , Cataplexia/epidemiologia , Feminino , Cadeias beta de HLA-DQ/genética , Hispânico ou Latino/genética , Hispânico ou Latino/estatística & dados numéricos , Humanos , Masculino , Orexinas/líquido cefalorraquidiano , Polissonografia , Razão de Masculinidade , Fases do Sono , Estados Unidos/epidemiologia , População Branca/genética , População Branca/estatística & dados numéricos
11.
Sleep ; 26(7): 809-10, 2003 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-14655912

RESUMO

OBJECTIVE: To explore whether acute destruction of hypocretin cells in a patient with narcolepsy could be detected and if the course of the disease could be reversed or altered by the use of prednisone for immunosuppression. DESIGN: Case report. SETTING: A sleep-clinic population in a tertiary-care hospital. PATIENT: An 8-year-old boy with a very acute recent (< 2 month) onset of sleepiness. METHODS: Sleep studies; fluid-attenuated inversion recovery and gadolinium magnetic resonance imaging studies with a focus on the hypothalamus; examinations of cerebrospinal fluid for cytology, protein, and hypocretin-1 levels; and HLA typing were performed. INTERVENTION: A 3-week regimen of 1 mg x kg(-1) x day(-1) of prednisone was administered in an attempt to modify the course of the disease. RESULTS AND CONCLUSION: Sleep evaluations were consistent with a diagnosis of narcolepsy. Hypocretin-1 was absent in the cerebrospinal fluid, and HLA-DQB1*0602 was present. All other results were within normal limits, and prednisone did not have any noticeable effects. Clinical manifestation of narcolepsy might occur when the hypocretin cell damage is too advanced to be reversible.


Assuntos
Antígenos HLA/imunologia , Imunossupressores/uso terapêutico , Peptídeos e Proteínas de Sinalização Intracelular , Narcolepsia/tratamento farmacológico , Narcolepsia/metabolismo , Neuropeptídeos/deficiência , Prednisona/uso terapêutico , Doença Aguda , Compostos Benzidrílicos/uso terapêutico , Proteínas de Transporte/líquido cefalorraquidiano , Estimulantes do Sistema Nervoso Central/uso terapêutico , Criança , Cicloexanóis/uso terapêutico , Humanos , Masculino , Modafinila , Narcolepsia/diagnóstico , Neuropeptídeos/líquido cefalorraquidiano , Orexinas , Polissonografia , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Cloridrato de Venlafaxina
12.
J Clin Sleep Med ; 10(9): 1011-8, 2014 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-25142772

RESUMO

OBJECTIVE: Cases of narcolepsy in association with psychotic features have been reported but never fully characterized. These patients present diagnostic and treatment challenges and may shed new light on immune associations in schizophrenia. METHOD: Our case series was gathered at two narcolepsy specialty centers over a 9-year period. A questionnaire was created to improve diagnosis of schizophrenia or another psychotic disorder in patients with narcolepsy. Pathophysiological investigations included full HLA Class I and II typing, testing for known systemic and intracellular/synaptic neuronal antibodies, recently described neuronal surface antibodies, and immunocytochemistry on brain sections to detect new antigens. RESULTS: Ten cases were identified, one with schizoaffective disorder, one with delusional disorder, two with schizophreniform disorder, and 6 with schizophrenia. In all cases, narcolepsy manifested first in childhood or adolescence, followed by psychotic symptoms after a variable interval. These patients had auditory hallucinations, which was the most differentiating clinical feature in comparison to narcolepsy patients without psychosis. Narcolepsy therapy may have played a role in triggering psychotic symptoms but these did not reverse with changes in narcolepsy medications. Response to antipsychotic treatment was variable. Pathophysiological studies did not reveal any known autoantibodies or unusual brain immunostaining pattern. No strong HLA association outside of HLA DQB1*06:02 was found, although increased DRB3*03 and DPA1*02:01 was notable. CONCLUSION: Narcolepsy can occur in association with schizophrenia, with significant diagnostic and therapeutic challenges. Dual cases maybe under diagnosed, as onset is unusually early, often in childhood. Narcolepsy and psychosis may share an autoimmune pathology; thus, further investigations in larger samples are warranted.


Assuntos
Narcolepsia/complicações , Transtornos Psicóticos/complicações , Esquizofrenia/complicações , Adolescente , Adulto , Idoso , Anticorpos Antinucleares/análise , Antipsicóticos/uso terapêutico , Criança , Diagnóstico Diferencial , Ensaio de Imunoadsorção Enzimática , Feminino , Alucinações/complicações , Teste de Histocompatibilidade/métodos , Humanos , Masculino , Narcolepsia/diagnóstico , Polissonografia , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/diagnóstico , Esquizofrenia/tratamento farmacológico , Inquéritos e Questionários
13.
Sci Transl Med ; 5(216): 216ra176, 2013 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-24353159

RESUMO

Narcolepsy, a disorder strongly associated with human leukocyte antigen (HLA)-DQA1*01:02/DQB1*06:02 (DQ0602), is characterized by excessive daytime sleepiness, cataplexy, and rapid eye movement sleep abnormalities. It is caused by the loss of ~70,000 posterior hypothalamic neurons that produce the wake-promoting neuropeptide hypocretin (HCRT) (orexin). We identified two DQ0602-binding HCRT epitopes, HCRT56-68 and HCRT87-99, that activated a subpopulation of CD4(+) T cells in narcolepsy patients but not in DQ0602-positive healthy control subjects. Because of the established association of narcolepsy with the 2009 H1N1 influenza A strain (pH1N1), we administered a seasonal influenza vaccine (containing pH1N1) to patients with narcolepsy and found an increased frequency of circulating HCRT56-68- and HCRT87-99-reactive T cells. We also identified a hemagglutinin (HA) pHA1 epitope specific to the 2009 H1N1 strain, pHA1275-287, with homology to HCRT56-68 and HCRT87-99. In vitro stimulation of narcolepsy CD4(+) T cells with pH1N1 proteins or pHA1275-287 increased the frequency of HCRT56-68- and HCRT87-99-reactive T cells. Our data indicate the presence of CD4(+) T cells that are reactive to HCRT in narcolepsy patients and possible molecular mimicry between HCRT and a similar epitope in influenza pH1N1, pHA1275-287.


Assuntos
Autoimunidade , Linfócitos T CD4-Positivos/imunologia , Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia , Vírus da Influenza A Subtipo H1N1/imunologia , Peptídeos e Proteínas de Sinalização Intracelular/imunologia , Narcolepsia/imunologia , Neuropeptídeos/imunologia , ADP-Ribosil Ciclase 1/imunologia , Adolescente , Adulto , Idoso , Sequência de Aminoácidos , Autoimunidade/genética , Estudos de Casos e Controles , Criança , Reações Cruzadas , Epitopos de Linfócito T/genética , Epitopos de Linfócito T/imunologia , Feminino , Cadeias alfa de HLA-DQ/genética , Cadeias beta de HLA-DQ/genética , Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética , Humanos , Vírus da Influenza A Subtipo H1N1/genética , Vacinas contra Influenza/efeitos adversos , Vacinas contra Influenza/imunologia , Influenza Humana/imunologia , Influenza Humana/virologia , Interferon gama/biossíntese , Peptídeos e Proteínas de Sinalização Intracelular/genética , Ativação Linfocitária , Masculino , Glicoproteínas de Membrana/imunologia , Pessoa de Meia-Idade , Mimetismo Molecular/genética , Mimetismo Molecular/imunologia , Dados de Sequência Molecular , Narcolepsia/etiologia , Narcolepsia/genética , Neuropeptídeos/genética , Orexinas , Homologia de Sequência de Aminoácidos , Pesquisa Translacional Biomédica , Gêmeos Monozigóticos , Adulto Jovem
14.
Sleep ; 35(9): 1247-55F, 2012 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-22942503

RESUMO

STUDY OBJECTIVES: To compare clinical, electrophysiologic, and biologic data in narcolepsy without cataplexy with low (≤ 110 pg/ml), intermediate (110-200 pg/ml), and normal (> 200 pg/ml) concentrations of cerebrospinal fluid (CSF) hypocretin-1. SETTING: University-based sleep clinics and laboratories. PATIENTS: Narcolepsy without cataplexy (n = 171) and control patients (n = 170), all with available CSF hypocretin-1. DESIGN AND INTERVENTIONS: Retrospective comparison and receiver operating characteristics curve analysis. Patients were also recontacted to evaluate if they developed cataplexy by survival curve analysis. MEASUREMENTS AND RESULTS: The optimal cutoff of CSF hypocretin-1 for narcolepsy without cataplexy diagnosis was 200 pg/ml rather than 110 pg/ml (sensitivity 33%, specificity 99%). Forty-one patients (24%), all HLA DQB1*06:02 positive, had low concentrations (≤ 110 pg/ml) of CSF hypocretin-1. Patients with low concentrations of hypocretin-1 only differed subjectively from other groups by a higher Epworth Sleepiness Scale score and more frequent sleep paralysis. Compared with patients with normal hypocretin-1 concentration (n = 117, 68%), those with low hypocretin-1 concentration had higher HLA DQB1*06:02 frequencies, were more frequently non-Caucasians (notably African Americans), with lower age of onset, and longer duration of illness. They also had more frequently short rapid-eye movement (REM) sleep latency (≤ 15 min) during polysomnography (64% versus 23%), and shorter sleep latencies (2.7 ± 0.3 versus 4.4 ± 0.2 min) and more sleep-onset REM periods (3.6 ± 0.1 versus 2.9 ± 0.1 min) during the Multiple Sleep Latency Test (MSLT). Patients with intermediate concentrations of CSF hypocretin-1 (n = 13, 8%) had intermediate HLA DQB1*06:02 and polysomnography results, suggesting heterogeneity. Of the 127 patients we were able to recontact, survival analysis showed that almost half (48%) with low concentration of CSF hypocretin-1 had developed typical cataplexy at 26 yr after onset, whereas only 2% had done so when CSF hypocretin-1 concentration was normal. Almost all patients (87%) still complained of daytime sleepiness independent of hypocretin status. CONCLUSION: Objective (HLA typing, MSLT, and sleep studies) more than subjective (sleepiness and sleep paralysis) features predicted low concentration of CSF hypocretin-1 in patients with narcolepsy without cataplexy.


Assuntos
Peptídeos e Proteínas de Sinalização Intracelular/líquido cefalorraquidiano , Peptídeos e Proteínas de Sinalização Intracelular/deficiência , Narcolepsia/líquido cefalorraquidiano , Neuropeptídeos/líquido cefalorraquidiano , Neuropeptídeos/deficiência , Adulto , Idade de Início , Biomarcadores/líquido cefalorraquidiano , Feminino , Seguimentos , Humanos , Masculino , Orexinas , Polissonografia/métodos , Valor Preditivo dos Testes , Curva ROC , Grupos Raciais/estatística & dados numéricos , Estudos Retrospectivos , Sensibilidade e Especificidade , Fases do Sono , Análise de Sobrevida
15.
Nat Genet ; 43(1): 66-71, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21170044

RESUMO

Growing evidence supports the hypothesis that narcolepsy with cataplexy is an autoimmune disease. We here report genome-wide association analyses for narcolepsy with replication and fine mapping across three ethnic groups (3,406 individuals of European ancestry, 2,414 Asians and 302 African Americans). We identify a SNP in the 3' untranslated region of P2RY11, the purinergic receptor subtype P2Y11 gene, which is associated with narcolepsy (rs2305795, combined P = 6.1 × 10⁻¹°, odds ratio = 1.28, 95% CI 1.19-1.39, n = 5689). The disease-associated allele is correlated with reduced expression of P2RY11 in CD8(+) T lymphocytes (339% reduced, P = 0.003) and natural killer (NK) cells (P = 0.031), but not in other peripheral blood mononuclear cell types. The low expression variant is also associated with reduced P2RY11-mediated resistance to ATP-induced cell death in T lymphocytes (P = 0.0007) and natural killer cells (P = 0.001). These results identify P2RY11 as an important regulator of immune-cell survival, with possible implications in narcolepsy and other autoimmune diseases.


Assuntos
Variação Genética , Narcolepsia/genética , Receptores Purinérgicos P2/genética , Negro ou Afro-Americano , Alelos , Povo Asiático , Estudos de Casos e Controles , Etnicidade/genética , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Humanos , Razão de Chances , Polimorfismo de Nucleotídeo Único , População Branca
18.
Nat Genet ; 41(6): 708-11, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19412176

RESUMO

Narcolepsy with cataplexy, characterized by sleepiness and rapid onset into REM sleep, affects 1 in 2,000 individuals. Narcolepsy was first shown to be tightly associated with HLA-DR2 (ref. 3) and later sublocalized to DQB1*0602 (ref. 4). Following studies in dogs and mice, a 95% loss of hypocretin-producing cells in postmortem hypothalami from narcoleptic individuals was reported. Using genome-wide association (GWA) in Caucasians with replication in three ethnic groups, we found association between narcolepsy and polymorphisms in the TRA@ (T-cell receptor alpha) locus, with highest significance at rs1154155 (average allelic odds ratio 1.69, genotypic odds ratios 1.94 and 2.55, P < 10(-21), 1,830 cases, 2,164 controls). This is the first documented genetic involvement of the TRA@ locus, encoding the major receptor for HLA-peptide presentation, in any disease. It is still unclear how specific HLA alleles confer susceptibility to over 100 HLA-associated disorders; thus, narcolepsy will provide new insights on how HLA-TCR interactions contribute to organ-specific autoimmune targeting and may serve as a model for over 100 other HLA-associated disorders.


Assuntos
Narcolepsia/genética , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Animais , Cromossomos Humanos Par 14/genética , Cromossomos Humanos Par 22/genética , Replicação do DNA/genética , Cães , Genótipo , Humanos , Hipotálamo/imunologia , Hipotálamo/patologia , Camundongos , Narcolepsia/imunologia , Polimorfismo de Nucleotídeo Único
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA